Geode Capital Management
ELVN icon

Geode Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Geode Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.4M Buy
1,407,202
+340,782
+32% +$14.5M ﹤0.01% 1433
2026
Q1 		$41.8M Buy
1,066,420
+17,698
+2% +$490K ﹤0.01% 1589
2025
Q4 		$16.2M Sell
1,048,722
-36,291
-3% -$723K ﹤0.01% 2126
2025
Q3 		$22.2M Buy
1,085,013
+202,260
+23% +$4.08M ﹤0.01% 1945
2025
Q2 		$17.7M Buy
882,753
+63,580
+8% +$1.2M ﹤0.01% 2017
2025
Q1 		$16.1M Buy
819,173
+56,455
+7% +$1.21M ﹤0.01% 2016
2024
Q4 		$17.2M Buy
762,718
+12,510
+2% +$324K ﹤0.01% 2051
2024
Q3 		$19.2M Buy
750,208
+67,813
+10% +$1.57M ﹤0.01% 2000
2024
Q2 		$15.9M Buy
682,395
+206,939
+44% +$4.36M ﹤0.01% 2051
2024
Q1 		$8.36M Buy
475,456
+10,799
+2% +$166K ﹤0.01% 2431
2023
Q4 		$6.43M Buy
464,657
+31,685
+7% +$388K ﹤0.01% 2575
2023
Q3 		$5.92M Buy
432,972
+18,528
+4% +$312K ﹤0.01% 2560
2023
Q2 		$8.46M Buy
414,444
+379,056
+1,071% +$7.66M ﹤0.01% 2384
2023
Q1 		$775K Buy
35,388
+956
+3% +$19.4K ﹤0.01% 3463
2022
Q4 		$563K Buy
34,432
+8,163
+31% +$130K ﹤0.01% 3609
2022
Q3 		$239K Buy
26,269
+12,334
+89% +$72.8K ﹤0.01% 4101
2022
Q2 		$68K Buy
13,935
+319
+2% +$1.56K ﹤0.01% 4700
2022
Q1 		$102K Sell
13,616
-78
-0.6% -$514 ﹤0.01% 4655
2021
Q4 		$123K Hold
13,694
– – ﹤0.01% 4657
2021
Q3 		$223K Buy
13,694
+826
+6% +$17.2K ﹤0.01% 4403
2021
Q2 		$406K Sell
12,868
-13,368
-51% -$415K ﹤0.01% 4033
2021
Q1 		$885K Buy
26,236
+661
+3% +$33.6K ﹤0.01% 3606
2020
Q4 		$2.25M Buy
25,575
+4,846
+23% +$407K ﹤0.01% 3020
2020
Q3 		$1.69M Buy
20,729
+142
+0.7% +$12.8K ﹤0.01% 2960
2020
Q2 		$2.27M Buy
+20,587
New +$2.3M ﹤0.01% 2772

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Geode Capital Management's ELVN Position: Q2 2026 in Review

Geode Capital Management increased its Enliven Therapeutics (ELVN) stake by 32% in Q2 2026, buying an estimated $14.5M and bringing the position to 1,407,202 shares worth $71.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1433.

Geode Capital Management first reported a position in ELVN in Q2 2020 and has held it in 25 quarters since. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Geode Capital Management held 1,407,202 shares of Enliven Therapeutics worth $71.4M as of Q2 2026.
  • Geode Capital Management bought 340,782 Enliven Therapeutics shares in Q2 2026, an estimated $14.5M.
  • Enliven Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1433 holding.
  • Geode Capital Management first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.